ReviewFrontiers in immunology2015
Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth.
Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 54 citations in OpenAlex.
- Genital inflammation screening for predicting sexually transmitted infections and bacterial vaginosis: an updated cost analysis from the GIFT study in Madagascar, South Africa, and Zimbabwe.BMC women's health · 2026Observational
- Therapeutic effect and mechanism of different doses of aspirin on preterm delivery in pregnant mice.PloS one · 2026Article
- Deciphering mechanisms leading to preterm birth through post-GWAS integration of multi-omics data.iScience · 2025Article
- The Utility of Human Milk Oligosaccharides against Group BACS central science · 2023Article
- Emerging role of toll-like receptors signaling and its regulators in preterm birth: a narrative review.Archives of gynecology and obstetrics · 2023Review
- Genetic variants associated with spontaneous preterm birth in women from India: a prospective cohort study.The Lancet regional health. Southeast Asia · 2023Article
- Clarithromycin prevents preterm birth and neonatal mortality by dampening alarmin-induced maternal-fetal inflammation in mice.BMC pregnancy and childbirth · 2022Article
- Maternal siRNA silencing of placental SAA2 mitigates preterm birth following intrauterine inflammation.Frontiers in immunology · 2022Article
- Macrophages exert homeostatic actions in pregnancy to protect against preterm birth and fetal inflammatory injury.JCI insight · 2021Article
- Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models.Science advances · 2021Article
- Screening of Chorioamnionitis Using Volatile Organic Compound Detection in Exhaled Breath: A Pre-clinical Proof of Concept Study.Frontiers in pediatrics · 2021Article
- Toll-like receptor 2/4 inhibitors can reduce preterm birth in mice.The Journal of international medical research · 2020Article
- Erythropoietin prevents LPS-induced preterm birth and increases offspring survival.American journal of reproductive immunology (New York, N.Y. : 1989) · 2020Article
- Targeting Toll-like receptor-4 to tackle preterm birth and fetal inflammatory injury.Clinical & translational immunology · 2020Review
- ASK1 promotes uterine inflammation leading to pathological preterm birth.Scientific reports · 2020Article
- Insight Into TLR4-Mediated Immunomodulation in Normal Pregnancy and Related Disorders.Frontiers in immunology · 2020Review
- Testing an infection model to explain excess risk of preterm birth with long-term iron supplementation in a malaria endemic area.Malaria journal · 2019Article
- Article
- The Vaginal Microenvironment: The Physiologic Role ofFrontiers in medicine · 2018Review
- Inhibition of Inflammatory Changes in Human Myometrial Cells by Cell Penetrating Peptide and Small Molecule Inhibitors of NFκB.Frontiers in immunology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preterm birth (PTB) at less than 37 weeks of gestation is the leading cause of neonatal morbidity and mortality. Intrauterine infection (IUI) due to microbial invasion of the amniotic cavity is the leading cause of early PTB (<32 weeks). Commensal genital tract Ureaplasma and Mycoplasma species, as well as Gram-positive and Gram-negative bacteria, have been associated with IUI-induced PTB. Bacterial activation of Toll-like receptors and other pattern recognition receptors initiates a cascade of inflammatory signaling via the NF-κB and p38 mitogen-activated protein kinase (MAPK) signaling pathways, prematurely activating parturition. Antenatal antibiotic treatment has had limited success in preventing PTB or fetal inflammation. Administration of anti-inflammatory drugs with antibiotics could be a viable therapeutic option to prevent PTB and fetal complications in women at risk of IUI and inflammation. In this mini-review, we will discuss the potential for anti-inflammatory drugs in obstetric care, focusing on the class of drugs termed "cytokine suppressive anti-inflammatory drugs" or CSAIDs. These inhibitors work by specifically targeting the NF-κB and p38 MAPK inflammatory signaling pathways. Several CSAIDs are discussed, together with clinical and toxicological considerations associated with the administration of anti-inflammatory agents in pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.